Reteplase appears to be another safe and effective thrombolytic option for the treatment of acute ischemic stroke, according to results from the randomized RAISE trial. When given within the first 4.5 ...

Reteplase is noninferior to alteplase for patients with ischemic stroke within 4.5 hours after symptom onset, according to a study published online June 14 in the New England Journal of Medicine to ...

A new trial has found the thrombolytic reteplase to be superior to alteplase in patients with acute ischemic stroke presenting within 4.5 hours of symptom onset, with an excellent functional outcome ...

Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...

Please provide your email address to receive an email when new articles are posted on . Reteplase was superior to alteplase at reducing disability after acute ischemic stroke. Mortality was similar ...

Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...

Washington, DC - The FDA has ordered Centocor, a division of Johnson & Johnson, to correct a series of statements on promotional materials for reteplase (Retavase ®, Centocor) that have been found to ...

HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply ...

Reteplase more likely to result in excellent functional outcome than alteplase for ischemic stroke within 4.5 hours of symptom onset. HealthDay News — Reteplase is noninferior to alteplase for ...